Assessment of F/HN-Pseudotyped Lentivirus as a Clinically Relevant Vector for Lung Gene Therapy (2012)

Griesenbach, U., Inoue, M., Meng, C., Farley, R., Chan, M., Newman, N. K., Brum, A., You, J., Kerton, A., Shoemark, A., Boyd, A. C., Davies, J. C., Higgins, T. E., Gill, D. R., Hyde, S. C., Innes, J. A., Porteous, D. J., Hasegawa, M. & Alton, E. W.

Am J Respir Crit Care Med, E-Pub Ahead of Print.

Pubmed     Back

RATIONAL: Our ongoing efforts to improve pulmonary gene transfer thereby enabling gene therapy for the treatment of lung diseases such as cystic fibrosis (CF) has led to the assessment of a lentiviral vector (SIV) pseudotyped with the Sendai virus envelope proteins F and HN.

OBJECTIVES: Here, we begin to place this vector onto a translational pathway to the clinic, by addressing some key milestones that have to be achieved.

MAIN RESULTS: These include: (1) a single dose produces lung expression for the life-time of the mouse (approximately 2 years), (2) only brief contact time is needed to achieve transduction, (3) repeated daily administration leads to a dose-related increase in gene expression, (4) repeated monthly administration to mouse lower airways is feasible without loss of gene expression, (5) there is no evidence of chronic toxicity during a 2 year study period, (6) F/HN-SIV transduction generates persistent gene expression in human differentiated airway cultures, and human lung slices and transduces freshly obtained primary human airway epithelial cells.

CONCLUSIONS: The data support F/HN-pseudotyped SIV as a promising vector for pulmonary gene therapy for a number of diseases including CF and we are now undertaking the necessary refinements to progress this vector into clinical trials.

Site map

 

Home
News
Contact Details
Follow us on Facebook
Events & Fundraising
Careers
Site Feedback
Site Search
The CF Trust

 

Information for Patients on Our Clinical Trial
Latest Clinical Trial News
Contact Details
Patient Identification Centres
Frequently Asked Questions

 

Consortium Members' Internal Website
About Us
How the Consortium Works
Profiles of the Strategy Group
Milestones
Community Review
Prof David Porteous OBE
Oxford University Gene Medicine
Centre for Molecular Medicine, Edinburgh
The Roslin Institute
Dep of Gene Therapy, Imperial

 

Our Research
Optimisation of pDNA
Aerosol Delivery
Viral Vectors Development
Assay Development
Core Facilities
Consortium Patents

 

Clinical Programme
GL67A/pGM169
Clinical Team
Tracking Study
The Run-in Study
Single Dose Clinical Trial
Multi Dose Clinical Trial

 

Cystic Fibrosis
What is CF?
History of CF
Discovery of the CFTR Gene
What Causes CF?
CFTR Protein Structure
Cystic Fibrosis Links

 

Funding
EME
DPFS
Gene Therapy
Introduction to CF Gene Therapy
Why use Gene Therapy for CF?
Other CF Gene Therapy Groups
Examples of Successful Gene Therapy
Gene Therapy Links

 

Publications
Publications in Journals
Conference Posters & Presentations
JustGeneTherapy Lecture, Sept 2012
Book Chapters
Lectures
Open Access Publications
Latest Publications

 

Medical Futures Innovation Award 2011
Introductory Video
What is a Lentivirus
Production of Lentiviruses
Progress to Date
DNAVec
Photo Gallery